Pulmonary Hypertension News

1 week ago | pulmonaryhypertensionnews.com | Lindsey Shapiro

On May 5, more than 80 organizations around the world will join to raise awareness of pulmonary hypertension (PH), a serious but often under-recognized cardiovascular disease affecting more than 75 million people worldwide. World Pulmonary Hypertension Day, an annual event spearheaded by PHAEurope, also aims to promote healthcare and treatment access for people with PH and support research efforts toward a cure.

1 week ago | pulmonaryhypertensionnews.com | Marisa Wexler |Anna Jeter |Mary Chapman

The PAH Initiative is hosting a video event in May to provide information about the benefits of exercise for people with pulmonary arterial hypertension (PAH). “The Power of Movement: Cardiopulmonary Rehabilitation for PAH” is part of the initiative’s PAH Today national broadcast series.

2 weeks ago | pulmonaryhypertensionnews.com | Margarida Maia |Marisa Wexler |Lindsey Shapiro |Steve Bryson

Heart failure related to pulmonary arterial hypertension (PAH) is becoming more common, with patients living fewer years in full health, a trend that’s predicted to continue, with more cases and deaths expected by 2050, a study showed. In the three decades from 1990 to 2021, women accounted for more cases of PAH than men, suggesting that future efforts should focus on better understanding sex-specific differences and tailoring interventions.

2 weeks ago | pulmonaryhypertensionnews.com | Margarida Maia |Jen Cueva

Pulmonary artery denervation (PADN), a procedure that targets overactive nerves involved in blood vessel constriction, significantly lessens high blood pressure in the lungs of people with pulmonary hypertension (PH), according to a meta-analysis of more than a dozen studies. Pooled data also showed that the approach was associated with significant improvements in heart function and exercise capacity, further supporting its “promise as a therapeutic intervention for PH,” the researchers wrote.

2 weeks ago | pulmonaryhypertensionnews.com | Margarida Maia |Andrea Lobo |Lindsey Shapiro |Marisa Wexler

Treatments approved for pulmonary arterial hypertension (PAH) may reduce by half the risk of serious complications or death in adults and adolescents who also have repaired congenital heart disease (CHD), pooled data analysis of three clinical trials shows. This risk was similarly reduced among the whole PAH patient population who participated in the trials and given either Uptravi (selexipag), Opsumit (macitentan), or Tracleer (bosentan).